Dr. Anthony Priestley has been appointed medical director at ICON’s Clinical Pharmacology Unit in Manchester, UK. Dr. Priestley has more than 11 years of experience in pharmaceutical R&D. He joins the company from LCG Bioscience, where he served as medical director and head of clinical research, as well as clinical pharmacologist, responsible for the planning and conduct of all clinical pharmacology operations for projects in reproductive health, neurology, autoimmunity and inflammatory diseases.

“We are delighted to welcome Dr. Priestly to the clinical pharmacology team at our translational medicine unit in Manchester,” said Dr. Thomas Frey, president, ICON Development Solutions. “His appointment is a further demonstration of our commitment to improving early drug development and enhancing our ability to offer sponsors the expertise, specialist procedures and patient populations necessary to more rapidly establish proof of concept.”